Is the delay in diagnosis of pulmonary tuberculosis related to exposure to fluoroquinolones or any antibiotic?

International Journal of Tuberculosis and Lung Disease

Volumn 15, Issue 8, 2011, Pages 1062-1068

  Wang, M ^a   FitzGerald, J M ^a   Richardson, K ^b   Marra, C A ^a,c   Cook, V J ^a,d   Hajek, J ^d   Elwood, R K ^a,d   Bowie, W R ^a   Marra, Fawziah ^a,d  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c PROVIDENCE HEALTH CARE RESEARCH INSTITUTE   (Canada)

^d BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

Author keywords

Antibiotics; Delay in diagnosis; Fluoroquinolones; Tuberculosis

Indexed keywords

ANTIINFECTIVE AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DELAYED DIAGNOSIS; DISEASE ASSOCIATION; DRUG EXPOSURE; DRUG USE; FEMALE; HUMAN; LUNG INFECTION; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; THERAPY DELAY;

ADULT; AGED; ANTI-BACTERIAL AGENTS; ANTITUBERCULAR AGENTS; BRITISH COLUMBIA; COHORT STUDIES; DELAYED DIAGNOSIS; DRUG PRESCRIPTIONS; FEMALE; FLUOROQUINOLONES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TUBERCULOSIS, PULMONARY;

EID: 79960423082     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.10.0734     Document Type: Article

References (21)

1. Ellis E, Long R. The epidemiology of tuberculosis in Canada. In: Standards Committee (Tuberculosis), Canadian Thoracic Society. Canadian tuberculosis standards, 6th ed. Ottawa, ON, Canada: Canadian Lung Association, 2007.
2. World Health Organization. Global tuberculosis control. WHO report 2010. WHO/HTM/TB/2010.7. Geneva, Switzerland: WHO, 2010. http://www.who.int/tb/ publications/global-report/2010/en/index.html Accessed May 2011.
3. Public Health Agency of Canada. Tuberculosis prevention and control 2008. Ottawa, ON, Canada: Public Health Agency of Canada, 2008. http://www.phac-aspc. gc.ca/tbpc-latb/surv-eng.php Accessed May 2011.
4. Joseph K, Korzeniewska-Kosela M, Muller N L, FitzGerald J M. Radiologic features of pulmonary tuberculosis: an assessment of 188 cases. Can Assoc Radiol J 1994; 45: 101-107. (Pubitemid 24162524)
5. FitzGerald J M. Essentials of tuberculosis control for the practicing physician: a statement by the Tuberculosis Committee of the Canadian Thoracic Society. Can Med Assoc J 1994; 150: 1561-1571.
6. Greenaway C, Menzies D, Fanning A, Grewal R, Yuan L, Fitz-Gerald J M; and the Canadian Collaborative Group in Nosocomial Transmission of Tuberculosis. Delay in diagnosis among hospitalized patients with active tuberculosis - predictors and outcomes. Am J Respir Crit Care Med 2002; 165: 927-933. (Pubitemid 34774659)
7. Shen L L. Quinolone-DNA interaction. In: Hooper D C, Wolfson J S, eds. Quinolone antimicrobial agents. 2nd ed. Washington DC, USA: American Society for Microbiology, 1993: pp 77-95.
8. Hermsen E D, Hovde L B, Konstantinides G N, Rotschafer J C. Mutant prevention concentrations of ABT-492, levofloxacin, moxifloxacin, and gatifloxacin against three common respiratory pathogens. Antimicrob Agents Chemother 2005; 49: 1633-1635. (Pubitemid 40463408)
9. Jones M E, Blosser-Middleton R S, Critchley I A, Karlowsky J A, Thornsberry C, Sahm D F. In vitro susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: a European multicenter study during 2000-2001. Clin Microbiol Infect 2003; 9: 590-599.
10. Lopez H, Vilches V, Scarano S, et al. Multicentre study of the in vitro evaluation of moxifloxacin and other quinolones against community acquired respiratory pathogens. Int J Antimicrob Agents 2001; 18: 379-382. (Pubitemid 33016353)
11. Mandell L A, Wunderink R G, Anzueto A, et al; Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 (Suppl 2): S27-72.
12. Mandell L A, Marrie T J, Grossman R F, Chow A W, Hyland R H, and The Canadian CAP Working Group. Summary of Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Disease Society and the Canadian Thoracic Society. Can J Infect Dis 2000; 11: 237-248.
13. Storla D G, Yimer S, Bjune G A. A systematic review of delay in the diagnosis and treatment of tuberculosis. BMC Public Health 2008; 8: 15.
14. Dooley K E, Golub J, Goes F S, Merz W G, Sterling T R. E mpiric treatment of community-acquired pneumonia with fluoroquinolones and delays in the treatment of tuberculosis. Clin Infect Dis 2002; 34: 1607-1612. (Pubitemid 34615446)
15. Yoon Y S, Lee H J, Yoon H I, et al. Impact of fluoroquinolones on the diagnosis of pulmonary tuberculosis initially treated as bacterial pneumonia. Int J Tuberc Lung Dis 2005; 9: 1215-1219. (Pubitemid 41735599)
16. Wang J, Hsueh P, Jan I, et al. Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas. Thorax 2006; 61: 903-908. (Pubitemid 44570312)
17. Golub J E, Bur S, Cronin W A, et al. Impact of empiric antibiotics and chest radiograph on delays in the diagnosis of tuberculosis. Int J Tuberc Lung Dis 2005; 9: 392-397. (Pubitemid 40524029)
18. Craig S E, Bettinson H, Sabin C A, Gillespie S H, Lipman M C I. Think TB! Is the diagnosis of pulmonary tuberculosis delayed by the use of antibiotics? Int J Tuberc Lung Dis 2009; 13: 208-213.
19. Chamberlayne R, Green B, Barer M L, Hertzman C, Lawrence W J, Sheps S B. Creating a population-based linked health database: a new resource for health services research. Can J Public Health 1998; 89: 270-273. (Pubitemid 28454432)
20. FitzGerald J M, Wang L, Elwood R K. Tuberculosis: control of the disease among aboriginal people in Canada. CMAJ 2000; 162: 351-355. (Pubitemid 30096840)
21. Devasia R A, Blackman A, Gebretsadik T, et al. Fluoroquinolone resistance in Mycobacterium tuberculosis: the effect of duration and timing of fluoroquinolone exposure. Am J Respir Crit Care Med 2009; 180: 365-370.